insights_auto
Why is EVGN down 8,59%?
Dive Deeperchevron_right
EVGN:NASDAQ
Evogene Ltd
USDÂ 0,38
arrow_downward
-8,59%(-0,036) 1D
USDÂ 0,43
arrow_upward
+13,68% (+0,052)todayPre-market
Closed: 28 Sep., 16:00:00 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EVGN...
Open
USDÂ 0,41
High
USDÂ 0,45
Low
USDÂ 0,35
Mkt. cap
5,94Â m
Avg. vol.
226,03Â k
Volume
5,65Â k
52-wk high
USDÂ 1,50
52-wk low
USDÂ 0,35
EPS
-USDÂ 0,91
Beta
1,40
Shares outstanding
15,80Â m
No. of employees
38
Open
USDÂ 0,41
High
USDÂ 0,45
Low
USDÂ 0,35
Mkt. cap
5,94Â m
Avg. vol.
226,03Â k
Volume
5,65Â k
52-wk high
USDÂ 1,50
52-wk low
USDÂ 0,35
EPS
-USDÂ 0,91
Beta
1,40
Shares outstanding
15,80Â m
No. of employees
38
News stories
From web sources and news partners
TipRanks
·
11 uur gelede
Evogene Updates SEC Filings With Weakening Mid-2026 Balance Sheet
Stock Titan
·
12 uur gelede
After about $2M in seed sales a year earlier, first-half revenue fell at Evogene (EVGN).
Profile
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
About Evogene Ltd